Autolus Therapeutics Stock Forecast, Price & News

-0.25 (-4.51 %)
(As of 04/16/2021 04:00 PM ET)
Today's Range
Now: $5.29
50-Day Range
MA: $6.19
52-Week Range
Now: $5.29
Volume420,696 shs
Average Volume771,594 shs
Market Capitalization$276.91 million
P/E RatioN/A
Dividend YieldN/A
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company is developing AUTO1 and AUTO3 for B cell malignancies; AUTO2 and AUTO8 for the treatment of multiple myeloma; AUTO1/22 for the treatment of dual-targeting CAR-T; AUTO3NG for the treatment of hematological cancer; AUTO4 and AUTO5 for T cell lymphoma; AUTO6NG for the treatment of programmed T cell therapies; AUTO6 for the treatment of neuroblastoma; and AUTO7 for the treatment of prostate cancer. Autolus Therapeutics plc was founded in 2014 and is headquartered in London, the United Kingdom.
Autolus Therapeutics logo

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Current SymbolNASDAQ:AUTL
Year FoundedN/A



Sales & Book Value

Annual Sales$2.91 million
Book Value$5.67 per share


Net Income$-123,850,000.00
Net Margins-8,652.90%


Market Cap$276.91 million
Next Earnings Date5/6/2021 (Estimated)
OptionableNot Optionable


Autolus Therapeutics Plc(AUTL)
March 17, 2021 |
Autolus Therapeutics's Earnings: A Preview
March 3, 2021 |
See More Headlines


Overall MarketRank

1.28 out of 5 stars

Medical Sector

838th out of 2,024 stocks

Biological Products, Except Diagnostic Industry

117th out of 177 stocks

Analyst Opinion: 3.4Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -
-0.25 (-4.51 %)
(As of 04/16/2021 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive AUTL News and Ratings via Email

Sign-up to receive the latest news and ratings for AUTL and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Autolus Therapeutics (NASDAQ:AUTL) Frequently Asked Questions

Is Autolus Therapeutics a buy right now?

8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Autolus Therapeutics in the last twelve months. There are currently 2 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Autolus Therapeutics stock.
View analyst ratings for Autolus Therapeutics
or view top-rated stocks.

What stocks does MarketBeat like better than Autolus Therapeutics?

Wall Street analysts have given Autolus Therapeutics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Autolus Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Autolus Therapeutics' next earnings date?

Autolus Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, May 6th 2021.
View our earnings forecast for Autolus Therapeutics

How were Autolus Therapeutics' earnings last quarter?

Autolus Therapeutics plc (NASDAQ:AUTL) posted its earnings results on Wednesday, March, 3rd. The company reported ($0.83) earnings per share for the quarter, missing the consensus estimate of ($0.77) by $0.06. The business had revenue of $0.40 million for the quarter, compared to analyst estimates of $0.43 million. Autolus Therapeutics had a negative trailing twelve-month return on equity of 54.01% and a negative net margin of 8,652.90%.
View Autolus Therapeutics' earnings history

How has Autolus Therapeutics' stock price been impacted by COVID-19 (Coronavirus)?

Autolus Therapeutics' stock was trading at $6.77 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, AUTL stock has decreased by 21.9% and is now trading at $5.29.
View which stocks have been most impacted by COVID-19

What price target have analysts set for AUTL?

8 Wall Street analysts have issued 12 month target prices for Autolus Therapeutics' shares. Their forecasts range from $9.00 to $38.00. On average, they expect Autolus Therapeutics' stock price to reach $21.71 in the next year. This suggests a possible upside of 310.5% from the stock's current price.
View analysts' price targets for Autolus Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Autolus Therapeutics' key executives?

Autolus Therapeutics' management team includes the following people:
  • Dr. Christian Martin Itin, Chairman & CEO (Age 57, Pay $4.29M)
  • Dr. Martin Pule MBBS, Founder, Sr. VP & Chief Scientific Officer (Age 49)
  • Mr. Andrew J. Oakley, Sr. VP & CFO (Age 59)
  • Mr. Christopher Vann, Sr. VP & COO (Age 56)
  • Mr. David Brochu, Sr. VP & Chief Technical Officer (Age 65)
  • Dr. Lucinda Crabtree Ph.D., VP of IR & Corp. Communications
  • Dr. Muhammad Al-Hajj Ph.D., Sr. VP of Translational Sciences (Age 50)
  • Mr. Vishal Mehta, VP & Head of Clinical Operations
  • Mr. Brent Rice, VP & Chief Commercial Officer
  • Mr. Matthias Alder, Sr. VP, Chief Bus. Officer & Sec. (Age 56)

Who are some of Autolus Therapeutics' key competitors?

What other stocks do shareholders of Autolus Therapeutics own?

When did Autolus Therapeutics IPO?

(AUTL) raised $125 million in an initial public offering on Friday, June 22nd 2018. The company issued 7,800,000 shares at a price of $15.00-$17.00 per share. Goldman Sachs and Jefferies acted as the underwriters for the IPO and Wells Fargo Securities and William Blair were co-managers.

What is Autolus Therapeutics' stock symbol?

Autolus Therapeutics trades on the NASDAQ under the ticker symbol "AUTL."

How do I buy shares of Autolus Therapeutics?

Shares of AUTL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Autolus Therapeutics' stock price today?

One share of AUTL stock can currently be purchased for approximately $5.29.

How much money does Autolus Therapeutics make?

Autolus Therapeutics has a market capitalization of $276.91 million and generates $2.91 million in revenue each year. The company earns $-123,850,000.00 in net income (profit) each year or ($2.88) on an earnings per share basis.

How many employees does Autolus Therapeutics have?

Autolus Therapeutics employs 376 workers across the globe.

What is Autolus Therapeutics' official website?

The official website for Autolus Therapeutics is

Where are Autolus Therapeutics' headquarters?

Autolus Therapeutics is headquartered at FOREST HOUSE 58 WOOD LANE WHITE CITY, LONDON X0, W12 7RZ.

How can I contact Autolus Therapeutics?

Autolus Therapeutics' mailing address is FOREST HOUSE 58 WOOD LANE WHITE CITY, LONDON X0, W12 7RZ. The company can be reached via phone at 44-20-3829-6230 or via email at [email protected]

This page was last updated on 4/18/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.